Jury Finds Against Illumina
LadaTech filed suit against Illumina in 2010. The jury found that Illumina directly infringed, infringed by the doctrine of equivalents (beyond literal limits) and indirectly infringed by inducement. The jury came to its decision on its first day of deliberation. Damages have not yet been determined.
Larchmont, NY 3/1/12; San Diego, CA 3/1/12—A Delaware District Court jury has found that certain Illumina sample preparation and cluster generation kits infringe LadaTech’s US Patent No. 6,107,023 (see IBO 4/30/10). According to LadaTech, the patent covers the DNA amplification process required for sample preparation and cluster station amplification steps. The jury also found the patent to be valid. Illumina stated that the judge in the case had granted summary judgment that its cluster generation kits and products, when used with third-party sample preparation kits, do not infringe the patent. Illumina stated that the trial will now move to its next phase, in which Illumina can demonstrate that the patent is unenforceable. LadaTech is jointly owned by GlaxoSmithKline and IP Finance Holdings.
